SCOHIA presented the results of a phase 1 clinical trial for SCO-267, an orally bioavailable GPR40 full agonist, at the Virtual 81st Scientific Sessions - American Diabetes Association, June 25-29, 2021.
“SCOHIA PHARMA presents clinical results of SCO-267 to help treat diabetes.“
First in human, single and repeated-dose study of SCO-267, a GPR40 full agonist, in healthy adults and subjects with glucose intolerance
The presentation is available on the company's website (https://www.scohia.com/eng/).
Free fatty acid receptor 1 (GPR40) is a G protein-coupled receptor expressed in pancreatic islet and enteroendocrine cells, and SCO-267 is potentially a first in class full agonist of this receptor¹ˉ⁴. To the best of our knowledge, we are the first to reveal the effects of single- and multiple-oral doses of GPR40 full agonist in healthy adults and diabetic patients. SCO-267 was safe and well tolerated at all tested doses, and exhibited good potential for once daily dosing. In this study, we demonstrated that SCO-267-mediated full agonism of GPR40 stimulates the secretion of both islet and gut hormones, including insulin, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and peptide YY in humans⁵. Oral administration of SCO-267 remarkably decreased fasting hyperglycemia and improved glycemic control during an oral glucose tolerance test in diabetic patients, without inducing hypoglycemia. These results collectively suggest a clinical potential of SCO-267 in treating diabetes. Based on its feature of stimulating islet and gut hormones, which regulate metabolism and body weight, SCO-267 may exhibit clinical benefits in treating diabetes, obesity, and nonalcoholic steatohepatitis. Therefore, SCO-267 is currently being prepared for a phase 2 clinical trial.See all the latest jobs in Pharmaceutical